RNA
Atrium Therapeutics·NASDAQ
--
--(--)
--
--(--)
RNA fundamentals
During Q4 2025, Atrium Therapeutics (RNA) reported revenue of 859.00K, a YoY change of -71.11%. Net income was -29.14M, a YoY change of -153.09%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q4,2024 | Q4,2025 | TTM |
|---|
Start Date | Oct 1, 2024 | Oct 1, 2025 | -- |
End Date | Dec 31, 2024 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | -- |
Revenue | 2.97M -- | 859.00K -71.11% | -- -- |
Pretax Income From Continuing Operations | -6.25M -- | -29.10M -365.86% | -- -- |
Income Tax Expense | 5.26M -- | 34.00K -99.35% | -- -- |
Net Income | -11.51M -- | -29.14M -153.09% | -- -- |
Total Comprehensive Income | -11.51M -- | -29.14M -153.09% | -- -- |
You can ask Aime
What is Atrium Therapeutics's gross profit margin?What were the key takeaways from Atrium Therapeutics's earnings call?What is the market's earnings forecast for Atrium Therapeutics next quarter?Did Atrium Therapeutics beat or miss consensus estimates last quarter?What does Atrium Therapeutics do and what are its main business segments?What were the key takeaways from Atrium Therapeutics’s earnings call?What factors drove the changes in Atrium Therapeutics's revenue and profit?What is the revenue and EPS growth rate for Atrium Therapeutics year over year?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
